Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
Back to JobsSAN DIEGO , Feb. 16, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced two upcoming presentations on the OTO-413 hearing loss program at the 49 th Annual Scientific and
Apply Now